Abstract: A peptide for treating rheumatoid arthritis and use thereof are provided, and a peptide consisting of an amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 3, or SEQ ID NO: 5 or a polynucleotide encoding the same, and a pharmaceutical composition for treating rheumatoid arthritis or a health functional food composition for improving rheumatoid arthritis, each including the peptide, are provided.

Abstract: A cylindrical secondary battery includes: an electrode assembly including a first electrode plate, a separator, and a second electrode plate; a center pin extending along a winding axis of the electrode assembly, the center pin including an insulating material and having a flange on at least one of an upper end and a lower end thereof; a case accommodating the electrode assembly and the center pin; a terminal extending through an upper end of the case and electrically connected to the first electrode plate of the electrode assembly; and a cap plate sealing a lower end of the case.

Abstract: A cylindrical secondary battery and a manufacturing method of a secondary battery are provided. A manufacturing method of a cylindrical secondary battery includes: winding an electrode assembly to expose a first electrode uncoated portion and a second electrode uncoated portion to opposite ends in a longitudinal direction; bending at least some portions of the first electrode uncoated portion and the second electrode uncoated portion of the electrode assembly in a direction by pressing the first electrode uncoated portion and the second electrode uncoated portion; welding electrode collector plates to ends of the bent first and second electrode uncoated portions; and inserting and sealing the electrode assembly into a cylindrical case.

Abstract: The present invention relates to a culture medium composition for culturing keratinocytes, and more specifically, to a culture medium composition for establishing or culturing keratinocytes, comprising calcium, an epidermal growth factor, and albumin According to the present invention, when keratinocytes are cultured using the culture medium of the present invention, the keratinocytes can be effectively proliferated within a short time, thus making it possible to more quickly obtain a desired number of the cells during the development of a therapeutic agent using the keratinocytes, and the activity of the keratinocytes is improved, and thus the culture medium of the present invention can be useful in the fields of keratinocyte research and the development of therapeutic agents.

Abstract: The present invention relates to a culture medium composition obtained by further adding at least one selected from the group consisting of rotenone and albumin to a serum-free medium prepared through a CAMPs technology. It has been ascertained that the proliferation of dermal papilla cells and maintenance of characteristics thereof during culturing can be improved by regulating the concentration of rotenone and albumin, and since the culture medium composition is a serum-free chemical medium comprising no serum, there is no risk of side effects, which can be caused by using a conventional serum medium, during use on the human body. The culture medium composition of the present invention obtained by further adding at least one selected from the group consisting of rotenone and albumin to a serum-free medium, or dermal papilla cells cultured through the composition can be effectively used in the development of therapeutic agents for hair loss prevention and hair growth promotion.

Abstract: A drug conjugate, composition, and method for delivering active antimicrobials based on existing antibiotics through a hexose phosphate transporter (UhpT) by conjugating the antimicrobials with non-metabolizable hexose phosphates. Methods of co-administering antibiotics with non-metabolizable hexose phosphates as antimicrobials are also disclosed. Non-metabolizable hexose phosphates can constitutively and strongly induce expression of UhpT which significantly improves the efficacy and/or antimicrobial spectrum of antibiotics. This drug conjugate, composition and method will permit reuse of many FDA approved antibiotics that have been abandoned or fallen into disuse due to their current low efficacy and/or resistance to these antibiotics by pathogens.

Abstract: The present application relates to a novel compound having inhibitory activity on prostaglandin E2 receptor and uses thereof, and provides a compound represented by formula I, a solvate, stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the same, and a method of using the same.

Abstract: An embodiment of the present invention relates to a cylindrical secondary battery in which the current collecting structure has been improved. According to the present invention, an elastic part is provided integrally with or separably from a current collecting plate, and thus shocks from external vibration can be absorbed. Thus, the issue in which the substrate of an electrode assembly is squashed or compacted can be minimized.

Abstract: An embodiment of the present invention relates to a cylindrical secondary battery which may comprise: a cylindrical can; an electrode assembly accommodated in the can and formed by stacking a first electrode plate, a separator, and a second electrode plate and winding in a cylindrical shape, wherein a first electrode uncoated portion of the first electrode plate protruding at one end in the longitudinal direction and a second electrode uncoated portion of the second electrode plate protruding at the other end thereof; a cap assembly coupled to one side of the can in a state in which the electrode assembly is accommodated in the can; a first electrode current collector plate which is located between the first electrode uncoated portion and the can and electrically connected to the first electrode uncoated portion and the cap assembly; a second electrode current collector plate which is located between the second electrode uncoated portion and the cap assembly and electrically connected to the second electrode

Abstract: A cylindrical secondary battery includes: an electrode assembly including a positive electrode plate having a positive electrode multi-tab, a separator, and a negative electrode plate having a negative electrode multi-tab, the positive electrode plate, the separator, and the negative electrode plate being laminated and wound; a cylindrical can accommodating the electrode assembly; a cap plate coupled at an upper end of the cylindrical can and being electrically connected to the negative electrode multi-tab; and a positive electrode terminal protruding upwardly through the cap plate and being electrically connected to the positive electrode multi-tab.

Abstract: The present invention relates to a secondary battery having improved output and safety. In one embodiment, disclosed is a secondary battery comprising: an electrode assembly comprising a first electrode, a second electrode and a separator; a case for accommodating the electrode assembly; and a cap assembly coupled to the upper part of the case, wherein the first electrode comprises a first current collector, a first active material layer in which the first active material layer is applied onto the first current collector, a first uncoated area on which a first active material is not applied, and a first electrode tab electrically connected to the first current collector, and the first electrode tab comprises a current collection tab, which is a part of the first current collector, and a lead tab attached to the first current collector.

Abstract: Disclosed is an energy self-sufficient real time bio-signal monitoring and nutrient and/or drug delivery system based on salinity gradient power generation. The energy self-sufficient real time bio-signal monitoring and/or nutrient delivery system based on salinity gradient power generation includes: an electricity generation and nutrient and/or drug delivery module including a reverse electrodialysis device which generates electricity by using a nutrient and/or drug solution and discharge a diluted nutrient solution; and a bio-signal measuring unit inserted into the electricity generation and nutrient and/or drug delivery module and configured to receive electricity from the electricity generation and nutrient and/or drug delivery module and measure a bio-signal.

Abstract: A novel assay which can differentiate a neutralizing antibody from non-neutralizing antibody which can be easily visualized, for example, by a portable UV lamp, among other visualization techniques. This assay can produce results in about 30 minutes and can be performed by untrained individuals in a non-laboratory environment. Also described is an ELISA method for determining if a human possesses at least one type of neutralizing antibody against SARS-Cov-2.

Abstract: The present invention relates to a secondary battery supporting the center part of an electrode assembly to enhance stability and reliability. For example, disclosed is a secondary battery comprising: an electrode assembly formed by winding a first electrode plate, a separator and a second electrode plate; a case for accommodating the electrode assembly; a current collection plate electrically connected to the first electrode plate and coupled to the upper part of the electrode assembly; and a core insulation member coupled to a winding center of the electrode assembly at the upper part of the current collection plate, wherein the core insulation member includes an insertion part having an inner hole, and a flange part extending in the horizontal direction from the upper end of the insertion part.

Abstract: The present invention relates to a multivalent live influenza vaccine platform using a recombinant adenovirus. The present invention is a live attenuated vaccine platform using a recombinant virus and it is easy to inoculate because it is infected with the respiratory tract like influenza virus and exhibits a vaccine action and it is a multivalent vaccine which combines two types into one and it is a highly novel vaccine that does not need to mix viruses compared to vaccines using multiple combinations of one vaccine. The present invention is the first vaccine in which a gene obtained by fusion of two influenza antigen genes into one gene is incorporated into a recombinant virus. Instead of using the entire HA gene of influenza, but using a structurally independent HA1 gene, which is about half of the total HA gene, several types of HA genes could be fused into one.

Abstract: A display apparatus, a method for executing an application thereof, an external device remotely controlling the display apparatus, and a method for providing an application control screen thereof are provided. The display apparatus includes a display that displays an application execution screen, the application execution screen displaying an application; a communication unit that communicates with an external server and an external device that remotely controls the display apparatus; and a control unit that transmits to the external device a generation signal that instructs the external device to generate an application control screen in response to receiving an input command to execute the application, controls the communication unit to receive a command from the external device input through the application control screen, and operates the application according to the received command.

Abstract: A cylindrical secondary battery including a can including a circular bottom part and a cylindrical side part having an opened one end, an electrode assembly in which a first electrode plate, a second electrode plate, and a separator are wound and which is accommodated in the can, and a collecting plate arranged in a direction toward the first electrode plate. The first electrode plate and the collecting plate, and the second electrode plate and the bottom part are electrically connected to each other in a non-welding manner. According to the embodiment, since the electrode assembly and the collecting plate and also the electrode assembly and the can are electrically connected to each other without the welding, the electrode assembly may be prevented or reduced from being damaged by foreign substances generated during the welding, thereby improving stability of the secondary battery.

Abstract: The present invention relates to a humanized DR4 antibody gene having apoptosis-inducing activity, and a dual-acting chimeric antigen receptor T cell or natural killer cell therapeutic agent, a secretory DR4 scFv antibody recombinant protein synthesized by using a humanized DR4 scFv antibody gene (humanized anti-DR4 scFv) may be used as an anticancer drug specifically targeting DR4 by binding to DR4 expressed on surface of the cancer cells to induce apoptosis of the cancer cells. In addition, the chimeric antigen receptor (CAR) using the humanized DR4 scFv antibody gene is predicted to have a strong anticancer immune effect as a dual-acting cell therapeutic agent, which is capable of simultaneously inducing apoptosis in cancer cells by DR4 and exhibiting a cytotoxic effect for cytotoxic T lymphocytes or natural killer cells by binding to DR4 expressed on the surface of cancer cells, as a DR4-specific CAR-T cell or CAR-NK cell therapeutic agent.

Abstract: Disclosed is a method for generating a random number, which is performed by a computing device including at least one processor. The method for generating a random number may include: recognizing the number of detection times at which a single photon detector (SPD) detects a dark count; and generating a random number based on a bit value allocated to a section including the number of detection times among a plurality of sections.

Abstract: A method for controlling a control device includes receiving, from a broadcast receiver, first information regarding a content which is currently provided through the broadcast receiver, and displaying a UI corresponding to the content which is currently provided through the broadcast receiver among a plurality of UIs based on the received first information. The plurality of UIs includes a plurality of UI items for controlling the broadcast receiver, respectively. A control command is transmitted to the broadcast receiver in response to a user input selecting an UI item among the plurality of UI items for controlling the broadcast receiver.